Background: Today over 1 million people have hypertension in the world. 1.5 billion people have symptoms of the diseases living difficulty. The hyperpiesis is 64% brain hemorrhage causes, and 49% of heart attack diseases. Blood pressure or hyperpiesis is the leading cause of adult diseases in Mongolia. With hypertension diagnoses, 19811 people hospitalized in patient treatment and 46022 people have received outpatient care through Mongolia. The most present of Mongolians regularly use medicines for reducing arterial pressure. In this research, we chosen the Enap medicine that is used common; 5 mg, 10 mg and 20 mg Enap are used at imported and domestic industry in the pharmaceutical market, Mongolia. Aim: To research some indicators of Enap pharmaceutical market which is used common in the treatment by Mongolians. Method: Based on the statistics from Mongolian Customs, when we research about the Enap market, we used the drug economic analysis methods including comparative research methods and content analysis research methods, respectively. Results: Our result shows that the 66.7% of all Enap in Mongolian pharmaceutical market is imported, and other 33.3% medicine is produced in domestic manufacturers, Mongolia. In Mongolia, 8 companies imports the Enap medicines from the biggest farms like KRKA, Denk Pharma, Berlin Chemie and Akrihin-akri. In the comparison research for Enap sales, there are 8 importer companies, the Х1 company sells the most, and it’s 22.4 times much than the lowest sales. In the research for Enap /10mg/average prices, the imported products cost 324 MNT but the domestic products cost 1525 MNT.